Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemoimmunotherapy Boosts Head and Neck Cancer Response

2.

Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill

3.

Novel radiotracer identifies biomarker for triple-negative breast cancer

4.

Discovery of breast cancer treatment resistance mechanism could lead to new hope for some

5.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot